| Serial Number | 79351833 |
| Word Mark | BICYCLE THERAPEUTICS |
| Filing Date | Friday, November 26, 2021 |
| Status | 700 - REGISTERED |
| Status Date | Tuesday, October 3, 2023 |
| Registration Number | 7178565 |
| Registration Date | Tuesday, October 3, 2023 |
| Mark Drawing | 5000 - Drawing with word(s) / letter(s) / number(s) in Stylized form |
| Published for Opposition Date | Tuesday, July 18, 2023 |
| Description of Mark | The mark consists of the wording BICYCLE in black with the two letters "C" stylized in gold over the word THERAPEUTICS in black. |
| Goods and Services | Pharmaceuticals, namely, preparations and products for use in the treatment and prevention of disease in the field of oncology for both solid and liquid tumours, for use in the treatment and prevention of metabolic disease, urology and renal disease, in the cardiovascular field, in the field of hematology, for use in the treatment and prevention of respiratory, chronic and acute inflammatory disease and auto-immune disorders, gastrointestinal disease, bacterial and viral infectious disease, neurological and psychiatric disorders; pharmaceutical products and preparations for use in the treatment and prevention of disease in the field of oncology; pharmaceutical products and preparations for use in the treatment and prevetion of disease in the field of ophthalmology; pharmaceutical products and preparations for use in the treatment and prevention of disease in the field of neurology; anti-infective pharmaceutical products and preparations; pharmaceutical products and preparations for the treatment and/or prevention of respiratory disease; pharmaceutical products and preparations for the treatment and/or prevention of cardiovascular disease; pharmaceutical products and preparations for the treatment and/or prevention of metabolic disease; pharmaceutical products and preparations for the treatment and/or prevention of viral infections; pharmaceutical products and preparations for use in diagnostics and imaging, namely, clinical imaging agents; pharmaceutical products and preparations for the treatment and/or prevention of renal disease; pharmaceutical products and preparations for the treatment and/or prevention of gastrointestinal disease; pharmaceutical products and preparations for the treatment and/or prevention of muscular skeletal disease |
| Indication of Colors claimed | The color(s) black and gold is/are claimed as a feature of the mark. |
| Goods and Services | Medical services; healthcare services for the treatment and prevention of disease in the field of oncology for both solid and liquid tumours, for the treatment and prevention of metabolic disease, urology and renal disease, cardiovascular diseases, for the treatment and prevention of disease in the field of hematology, for the treatment and prevention of respiratory, chronic and acute inflammatory disease and auto-immune disorders, gastrointestinal disease, bacterial and viral infectious disease, neurological and psychiatric disorders; pharmaceutical compounding services; medical consulting services; advisory services relating to pharmaceuticals; medical and pharmaceutical consultation and providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals; medical services in the field of oncology; medical services in the field of ophthalmology; medical services in the field of neurology; medical services in the field of anti-infectives; medical services in the field of respiratory disease; medical services in the field of cardiovascular disease; medical services in the field of metabolic disease; medical services in the field of the treatment and/or prevention of viral infections; medical services in the field of diagnostics and imaging; medical services in the field of renal disease; medical services in the field of gastrointestinal disease; medical services in the field of muscular skeletal disease; pharmaceutical compounding services in the field of oncology; pharmaceutical compounding services in the field of ophthalmology; pharmaceutical compounding services in the field of neurology; pharmaceutical compounding services in the field of anti-infectives; pharmaceutical compounding services in the field of respiratory disease; pharmaceutical compounding services in the field of cardiovascular disease; pharmaceutical compounding services in connection with metabolic disease; pharmaceutical compounding services in connection with the treatment and/or prevention of viral infections; pharmaceutical compounding services in connection with diagnostics and imaging; pharmaceutical compounding services in connection with renal disease; pharmaceutical compounding services in connection with gastrointestinal disease; pharmaceutical compounding services in connection with muscular skeletal disease; information, consultancy and advisory services relating to the aforesaid; medical testing for diagnostic or treatment purposes in the field of oncology for both solid and liquid tumours, metabolic disease, urology and renal disease, cardiovascular diseases, hematology, respiratory disease, chronic and acute inflammatory disease and auto-immune disorders, gastrointestinal disease, bacterial and viral infectious disease, neurological and psychiatric disorders |
| Disclaimer with Predetermined Text | "THERAPEUTICS" |
| Goods and Services | Scientific and technological services and research and design relating thereto, namely, scientific research, new product design services, and new study design services in the fields of the development of future human and veterinary medical treatments in the field of oncology for both solid and liquid tumors, metabolic disease, urology and renal disease, cardiovascular, hematology, respiratory, chronic and acute inflammatory disease and auto-immune disorders, gastrointestinal disease, bacterial and viral infectious disease, neurological and psychiatric disorders, diagnostic preparations and clinical imaging agents; industrial analysis and research services in the fields of oncology for both solid and liquid tumors, metabolic disease, urology and renal disease, cardiovascular, hematology, respiratory, chronic and acute inflammatory disease and auto-immune disorders, gastrointestinal disease, bacterial and viral infectious disease, neurological and psychiatric disorders, diagnostic preparations and clinical imaging agents; pharmaceutical research and development services; medical research and development services; pharmaceutical testing and medical and scientific research, namely, conducting clinical trials for others; medical and scientific research, namely, conducting clinical trials for others; research and development in the field of oncology; research and development in the field of ophthalmology; research and development in the field of neurology; research and development in the field of anti-infective pharmaceuticals; research and development in the field of respiratory disease; research and development in the field of cardiovascular disease; research and development in the field of metabolic disease; research and development in the field of antiviral drugs; research and development in the field of diagnostics and imaging; research and development in the field of renal disease; research and development in the field of gastrointestinal disease; research and development in the field of muscular skeletal disease; information consultancy and advisory services relating to the aforesaid |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, October 7, 2022 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, October 7, 2022 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, October 7, 2022 |
| Primary Code | 044 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Bicycletx Limited |
| Party Type | 30 - Original Registrant |
| Legal Entity Type | 99 - Other |
| Address | GB |
| Party Name | Bicycletx Limited |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 99 - Other |
| Address | GB |
| Party Name | Bicycletx Limited |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 99 - Other |
| Address | GB |
| Event Date | Event Description |
| Tuesday, January 30, 2024 | FINAL DECISION TRANSACTION PROCESSED BY IB |
| Tuesday, January 9, 2024 | FINAL DISPOSITION NOTICE SENT TO IB |
| Tuesday, January 9, 2024 | FINAL DISPOSITION PROCESSED |
| Wednesday, January 3, 2024 | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB |
| Saturday, December 16, 2023 | CHANGE OF NAME/ADDRESS REC'D FROM IB |
| Friday, December 1, 2023 | NEW REPRESENTATIVE AT IB RECEIVED |
| Tuesday, October 3, 2023 | NOTICE OF REGISTRATION CONFIRMATION EMAILED |
| Tuesday, October 3, 2023 | REGISTERED-PRINCIPAL REGISTER |
| Tuesday, July 18, 2023 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, July 18, 2023 | PUBLISHED FOR OPPOSITION |
| Wednesday, June 28, 2023 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, June 13, 2023 | EXAMINERS AMENDMENT MAILED |
| Tuesday, June 13, 2023 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Tuesday, June 13, 2023 | EXAMINER'S AMENDMENT ENTERED |
| Tuesday, June 13, 2023 | EXAMINERS AMENDMENT -WRITTEN |
| Monday, June 12, 2023 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Monday, June 12, 2023 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Monday, June 12, 2023 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Sunday, January 15, 2023 | REFUSAL PROCESSED BY IB |
| Friday, December 23, 2022 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Thursday, December 22, 2022 | REFUSAL PROCESSED BY MPU |
| Tuesday, October 11, 2022 | APPLICATION FILING RECEIPT MAILED |
| Saturday, October 8, 2022 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Friday, October 7, 2022 | NON-FINAL ACTION WRITTEN |
| Friday, October 7, 2022 | ASSIGNED TO EXAMINER |
| Friday, October 7, 2022 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Thursday, October 6, 2022 | SN ASSIGNED FOR SECT 66A APPL FROM IB |